NAC / Gillmore Stage (Transthyretin Cardiac Amyloidosis)

NAC / Gillmore Stage (Transthyretin Cardiac Amyloidosis) - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.

Open the NAC / Gillmore Stage (Transthyretin Cardiac Amyloidosis) → Runs in your browser. No signup, no tracking.

What this is

NAC / Gillmore Stage (Transthyretin Cardiac Amyloidosis) is one of 230 deterministic tools in Sophie Well's Clinical Scoring & Risk group. NAC / Gillmore Stage (Transthyretin Cardiac Amyloidosis) - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.

When to use it

Use this tool when you need a quick, citable reference. Every calculation runs entirely in your browser - no inputs leave your device, no account is required, no AI is involved. The site enforces a strict Content Security Policy and ships no analytics or third-party CDN.

References

Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799-2806. Expanded in Nitsche C, Patel RK, Hong Y, et al. Eur J Heart Fail. 2024;26(9):2008-2016. Read the source ↗

Worked example: stage 4

Sophie Well is a reference and educational tool. Not medical, legal, or financial advice. Does not replace clinician judgment, professional billing review, or legal counsel.

Built by Clay Good. Source on GitHub.